Uncategorized
Therapy enables 89% survival rate in myeloma patients
A combination treatment has demonstrated strong survival rates in patients with earlier-line relapsed or refractory multiple myeloma.
Talvey (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide showed a progression-free survival rate of up to 81.3% versus standard of care (51.2%) and an overall survival rate of 89.2% (versus 79.1% in standard of care) at 24 months.
The novel bispecific combination also reduced the risk of disease progression or death by 72%.
The results emerged from a Phase III study, reported by Johnson and Johnson and presented at the 2026 European Hematology Association (EHA) Annual Meeting.
“Daratumumab-based regimens have transformed the treatment of multiple myeloma and remain a foundational therapy across all stages of disease,” said Ester in ‘t Groen, EMEA Therapeutic Area Head, Haematology, Johnson & Johnson.
“The MonumenTAL-3 study builds on this legacy, combining daratumumab with talquetamab, the first GPRC5D bispecific antibody, to further expand the effective options available to patients in the relapsed/refractory setting.
“These findings reflect Johnson & Johnson’s commitment to leveraging the power of our portfolio to advance novel combination regimens that address the evolving and highly heterogeneous needs of patients living with multiple myeloma.”
“The MonumenTAL-3 findings underscore our commitment to bringing bispecific combinations into earlier lines of therapy, building on the strength and breadth of Johnson & Johnson’s multiple myeloma portfolio,” added Yusri Elsayed, Therapeutic Head, Oncology, Johnson & Johnson.
“These results add to our growing body of evidence across bispecific antibodies and reinforce our strategy of advancing differentiated immunotherapies to better match the right therapy to the right patient at each stage of disease.”
The post Therapy enables 89% survival rate in myeloma patients appeared first on Drug Discovery World (DDW).